Rib remodelling: long-term risks unclear

A narrower waist is an aesthetic outcome; it is not, by itself, a measure of surgical safety. That distinction matters when the operation changes the ribs rather than only soft tissue. A SheFinds report of 28 September 2026 discussed chest-wall risks. Mariam Qayum’s report on the advertising-supported beauty site drew partly on a practitioner’s social-media video. It provides media context, not proof of a general trend or treatment effectiveness.

A prospective study published on 13 October 2026 in Aesthetic Surgery Journal now adds a defined, short observation period: 100 consecutive patients were assessed before treatment and at six months. Eighty had RibXcar alone, and twenty also underwent body liposuction. The technique involves a controlled partial cut in a rib; it is distinct from removing a rib. The paper does not make every procedure marketed as rib remodelling interchangeable.

What six months can show

The abstract reports an 8% rate of minor complications and no pneumothorax or hemothorax—air or blood accumulating around a lung—in this series. Lung-function testing did not show statistically significant changes at six months in either group. Reported pain had resolved by that time, and BODY-Q satisfaction scores improved.

These findings are useful observations in the patients followed. They do not mean that risk is zero. A series of one hundred people may miss uncommon events, and a six-month assessment cannot answer questions about later problems. No statistically significant lung-function change is also not a guarantee that breathing is unaffected for every patient in every setting.

The greater reported waist reduction in the group also receiving liposuction cannot be attributed to rib surgery alone. The accessible abstract does not establish a randomized comparison. Baseline selection and the additional operation therefore matter when interpreting the difference; the larger number is not a promise of what an individual will achieve.

The wider evidence needs transparent interests

An earlier RibXcar cohort published on 14 July 2026 reported pneumothorax, hemothorax and chronic pain among 3,805 patients. Those observations cannot be pooled casually with this smaller series, but they illustrate why no such events in one study is not the same as no such risk.

The July paper also disclosed that Raúl Manzaneda Cipriani developed the technique and receives income from a proprietary surgical tip. He is a coauthor of the October study. This documented relationship makes independent confirmation especially relevant; it does not, on its own, invalidate results.

For treatment decisions, the unanswered issues are how the exact procedure performs over longer follow-up, how complications are recorded and how comparable alternatives perform. Waist measurements, satisfaction and safety need separate consideration. This report is based on the October abstract: its full text, detailed funding and complete current conflict statement were not accessible. The earlier disclosure is identified as such, not presented as a verified substitute for the October declaration.